Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un ensayo clínico de fase 2b de YN001 en adultos con aterosclerosis coronaria (PURIFY-TIMI 81)

3 de noviembre de 2026 actualizado por: Beijing Inno Medicine Co., Ltd.

Un ensayo clínico de fase 2b aleatorizado, multicéntrico, doble ciego, paralelo y controlado con placebo para evaluar la eficacia y seguridad de YN001 en adultos con aterosclerosis coronaria

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Descripción general del estudio

Descripción detallada

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

456

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • New South Wales
      • Penrith, New South Wales, Australia, 2750
        • Reclutamiento
        • Cannopy Clinical Research
        • Contacto:
    • Queensland
      • Brisbane, Queensland, Australia, 4064
        • Reclutamiento
        • Core Research Group Pty Ltd.
        • Contacto:
    • Victoria
      • Altona N., Victoria, Australia, 3025
        • Reclutamiento
        • Canopy Clinical Research
        • Contacto:
    • Manitoba
      • Winnipeg, Manitoba, Canadá, R2H 2A6
        • Aún no reclutando
        • St. Boniface Hospital
        • Contacto:
          • Shuangbo Liu
          • Número de teléfono: 204-237-2793
          • Correo electrónico: sliu@sbgh.mb.ca
    • Ontario
      • London, Ontario, Canadá, N5A 5A5
        • Aún no reclutando
        • London Health Sciences Centre
        • Contacto:
      • North York, Ontario, Canadá, M6B 3H7
        • Aún no reclutando
        • North York Diagnostic and Cardiac Centre
        • Contacto:
      • Toronto, Ontario, Canadá, M5B 1W8
        • Aún no reclutando
        • St. Michael's Hospital
        • Contacto:
      • Vaughan, Ontario, Canadá, L6A 4N9
        • Aún no reclutando
        • Cardiac Clinic
        • Contacto:
    • Toronto
      • Toronto, Toronto, Canadá, M5G 2N2
        • Aún no reclutando
        • Toronto General Hospital - University Health Network
        • Contacto:
    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801-4312
        • Reclutamiento
        • Heart Center Research, LLC
        • Contacto:
    • California
      • Covina, California, Estados Unidos, 91740
      • Lincoln, California, Estados Unidos, 95648
        • Aún no reclutando
        • Clinical Trials Research
        • Contacto:
      • Los Alamitos, California, Estados Unidos, 90720
        • Aún no reclutando
        • University of California Irvine Medical Center - Cardiovascular Center
        • Contacto:
      • Stanford, California, Estados Unidos, 94305-2200
        • Aún no reclutando
        • Stanford Health Care General Cardiology
        • Contacto:
          • Fahim Abbasi, MD
          • Número de teléfono: 650-723-6459
          • Correo electrónico: fahim@stanford.edu
      • Torrance, California, Estados Unidos, 90502-2006
        • Reclutamiento
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Contacto:
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33434
        • Aún no reclutando
        • Flourish Research - Boca Raton
        • Contacto:
      • Hialeah, Florida, Estados Unidos, 33016-1895
        • Reclutamiento
        • New Generation of Medical Research, LLC.
        • Contacto:
      • St. Petersburg, Florida, Estados Unidos, 33709
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303-3049
        • Aún no reclutando
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Contacto:
    • Idaho
      • Meridian, Idaho, Estados Unidos, 83642
        • Aún no reclutando
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Contacto:
          • Brian Nolan
          • Número de teléfono: 208-322-1680
          • Correo electrónico: bnolan@slhs.org
    • Illinois
      • Springfield, Illinois, Estados Unidos, 62781
        • Aún no reclutando
        • Southern Illinois University School of Medicine
        • Contacto:
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66211-1215
        • Reclutamiento
        • Midwest Heart & Vascular Specialists, LLC
        • Contacto:
          • Stephen Bloom, MD
          • Número de teléfono: 913-253-3000
          • Correo electrónico: sbloom@kc.rr.com
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1032
        • Reclutamiento
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Contacto:
          • Farhan Katchi, MD
          • Número de teléfono: 314-362-1291
          • Correo electrónico: katchif@wustl.edu
    • North Carolina
      • Raleigh, North Carolina, Estados Unidos, 27607
        • Aún no reclutando
        • NC Heart and Vascular Research, LLC
        • Contacto:
      • Winston-Salem, North Carolina, Estados Unidos, 27104-3520
        • Aún no reclutando
        • Javara Inc. - Wake Forest University Health Sciences
        • Contacto:
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73135
        • Aún no reclutando
        • South Oklahoma Heart Research, LLC
        • Contacto:
    • Pennsylvania
      • Camp Hill, Pennsylvania, Estados Unidos, 17011
        • Reclutamiento
        • Capital Area Research, LLC - Camp Hill
        • Contacto:
    • Texas
      • Amarillo, Texas, Estados Unidos, 79106
        • Reclutamiento
        • PharmaTex Research, LLC
        • Contacto:
      • Carrollton, Texas, Estados Unidos, 75010
        • Aún no reclutando
        • Pulse Care Heart and Vascular
        • Contacto:
      • Tomball, Texas, Estados Unidos, 77375
        • Aún no reclutando
        • DM Clinical Research - Dallas
        • Contacto:
    • An
      • Hefei, An, Porcelana, 230022
        • Reclutamiento
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Contacto:
          • Jianlong Wang, MD
          • Número de teléfono: 0086-13681292304
          • Correo electrónico: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, Porcelana, 230001
        • Reclutamiento
        • Anhui Provincial Hospital
        • Contacto:
          • Kangyu Chen, MD
          • Número de teléfono: 0086 18056005099
          • Correo electrónico: ustccky@126.com
        • Investigador principal:
          • Kangyu Chen, MD
        • Sub-Investigador:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100035
        • Reclutamiento
        • Beijing Jishuitan Hospital
        • Investigador principal:
          • Wei Liu, MD
        • Contacto:
          • Qingwei Ji, MD
          • Número de teléfono: 0086 18376642655
          • Correo electrónico: jqwl24@163.cou
        • Investigador principal:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, Porcelana, 100029
        • Reclutamiento
        • Anzhen Hospital
        • Contacto:
          • Yuyang Liu, MD
          • Número de teléfono: 0086 010-64456488
          • Correo electrónico: liuyy803803@163.com
        • Investigador principal:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, Porcelana, 101100
        • Aún no reclutando
        • Beijing Luhe Hospital
        • Contacto:
    • Fujian
      • Fuzhou, Fujian, Porcelana, 350001
        • Reclutamiento
        • Fujian Medical University Union Hospital
        • Contacto:
        • Investigador principal:
          • Mingfang Ye, MD
        • Sub-Investigador:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, Porcelana, 730030
        • Reclutamiento
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Contacto:
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510080
        • Reclutamiento
        • Guangdong Provincial People's Hospital
        • Contacto:
        • Contacto:
    • Heilongjiang
      • Daqing, Heilongjiang, Porcelana, 163316
        • Reclutamiento
        • Daqing People's Hospital
        • Contacto:
      • Harbin, Heilongjiang, Porcelana, 150001
        • Reclutamiento
        • The First Affiliated Hospital of Harbin Medical University
        • Contacto:
          • Lu Fu, MD
          • Número de teléfono: 0086 137 9668 4968
          • Correo electrónico: fuluyidayi@163.com
        • Investigador principal:
          • Lu Fu, MD
        • Investigador principal:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, Porcelana, 430071
        • Reclutamiento
        • Zhongnan Hospital of Wuhan University
        • Contacto:
          • Xiaorong Hu, MD
          • Número de teléfono: 0086 15927681634
          • Correo electrónico: huzrzn@whu.edu.cn
        • Investigador principal:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, Porcelana, 410008
        • Reclutamiento
        • The Second Xiangya Hospital fo Central South University
        • Contacto:
          • Xinqun Hu, MD
          • Número de teléfono: 0086-13307313627
          • Correo electrónico: huxinqungs@163.com
    • Jilin
      • Changchun, Jilin, Porcelana, 130033
        • Reclutamiento
        • The First Hospital of Jilin University
        • Investigador principal:
          • Qian Tong, MD
        • Contacto:
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110015
        • Reclutamiento
        • The People's Hospital of Liaoning Province
        • Investigador principal:
          • Ying Liu, MD
        • Contacto:
    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 710068
        • Reclutamiento
        • Shaanxi Provincial People's Hospital
        • Contacto:
          • Xiling Shou, MD
          • Número de teléfono: 0086 18966700335
          • Correo electrónico: shouxiling@163.com
    • Shandong
      • Jinan, Shandong, Porcelana
        • Reclutamiento
        • Central Hospital Affiliated to Shandong First Medicial University
        • Contacto:
          • Guohai Su, MD
          • Número de teléfono: 0086 19953193319
          • Correo electrónico: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200032
        • Reclutamiento
        • Fudan University-Zhongshan Hospital
        • Investigador principal:
          • Junbo Ge, MD
        • Contacto:
        • Sub-Investigador:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, Porcelana, 200001
        • Reclutamiento
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Contacto:
        • Investigador principal:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610041
        • Reclutamiento
        • West China Hospital of Sichuan University
        • Contacto:
          • Yong He, MD
          • Número de teléfono: 0086 18980602038
          • Correo electrónico: zznnyeah@163.com
        • Investigador principal:
          • Yong He, MD
      • Chengdu, Sichuan, Porcelana, 610072
        • Reclutamiento
        • Sichuan Provincial People's Hospital
        • Contacto:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300211
        • Reclutamiento
        • The Second Hospital of Tianjin Medical University
        • Contacto:
          • Tong Liu, MD
          • Número de teléfono: 0086 13902183163
          • Correo electrónico: liutongdoc@126.com
        • Investigador principal:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, Porcelana, 300121
        • Reclutamiento
        • Tianjin People's Hospital
        • Investigador principal:
          • Zhuhua Yao, MD
        • Contacto:
          • Zhuhua Yao, MD
          • Número de teléfono: 0086 13902199877
          • Correo electrónico: tjyzhpci@163.com
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310006
        • Reclutamiento
        • Zhejiang Provincial People's Hospital
        • Contacto:
          • Lihong Wang, MD
          • Número de teléfono: 0086-13666690598
          • Correo electrónico: wlhhz@hotmail.com
      • Suzhou, Zhejiang, Porcelana, 215006
        • Reclutamiento
        • The First Affiliated Hospital of Soochow University
        • Contacto:
      • Wenzhou, Zhejiang, Porcelana, 325000
        • Reclutamiento
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Experimental: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Comparador de placebos: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Relative change from baseline in coronary NCPV at Week 13
Periodo de tiempo: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Periodo de tiempo: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Periodo de tiempo: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Periodo de tiempo: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Periodo de tiempo: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Periodo de tiempo: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Periodo de tiempo: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Periodo de tiempo: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Periodo de tiempo: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Periodo de tiempo: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Periodo de tiempo: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Periodo de tiempo: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Periodo de tiempo: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Periodo de tiempo: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Director de estudio: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de julio de 2026

Finalización primaria (Estimado)

31 de julio de 2027

Finalización del estudio (Estimado)

31 de marzo de 2029

Fechas de registro del estudio

Enviado por primera vez

2 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de abril de 2026

Publicado por primera vez (Actual)

9 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • YN001-203
  • IND 157167 (Identificador de registro: Beijing Inno Medicine Co., Ltd.)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir